Active Surveillance White Paper
For many patients with lower-risk localized prostate cancer, forgoing or delaying definitive therapy through active surveilla [...]
Identifying Patients Who Will Benefit From Intensified Prostate Cancer...
Identifying men with high-risk, non-metastatic prostate cancer who will truly benefit from intensified treatment from therape [...]
U.S. FDA Grants Artera Breakthrough Device Designation for AI-Powered...
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced to [...]
AI Tool Accurately Predicts Prostate Cancer Outcomes Across Racial...
Mack Roach III, MD, professor of radiation oncology, medical oncology, and urology at the University of California, San Franc [...]
Multimodal AI Shows No Evidence of Bias in Prostate...
The study evaluated the performance of a multimodal artificial intelligence model to close gaps in care and validate that AI [...]
Artera Bullish on Prostate Cancer Test Following NYS Approval,...
NEW YORK – Startup firm Artera is continuing to make commercial progress with its artificial intelligence-based prostate canc [...]
Artera Product Webinar – June 2025
The ArteraAI Prostate Test is transforming the risk stratification landscape for treating localized prostate cancer. Watch th [...]
Artera Launches Registry Trial to Measure Real-World Impact and...
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced th [...]